[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Reduced Dose Hypofractionated Radiotherapy (3Gy X 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): a Multisite Phase 2 Randomized Trial


Description

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and/or effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.PRIMARY OBJECTIVE: I. To show that 9 Gy in 3 fractions has significantly reduced acute toxicity (grade ≥ 2 adverse events at least possibly related to radiation treatment within 14 days after the end of radiation treatment (according to Common Terminology Criteria for Adverse Ev

Trial Eligibility

Inclusion Criteria: * Age ≥ 18 years * Histological confirmation of indolent B-cell lymphoma that can include any of the following: * Follicular lymphoma (grade 1 or 2 or 3A) * Marginal zone lymphoma (nodal or extranodal) * Any stage disease * Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3 * Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only * Provide written informed consent * Ability to complete questionnaire(s) by themselves * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items * Confirmation from radiation oncologist of suitability to participate in study Exclusion Criteria: * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * T-cell lymphoma * Small and chronic lymphocytic lymphoma * Grade 3B follicular lymphoma

Study Info

Organization

Mayo Clinic


Primary Outcome

Incidence of grade 2 or higher acute adverse events (AEs)


Outcome Timeframe Up to 14 days after radiation treatment

NCTID NCT06386315

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2024-05-15

Completion Date 2026-05-30

Enrollment Target 112

Interventions

PROCEDURE Computed Tomography

PROCEDURE Endoscopic Procedure

RADIATION Involved-site Radiation Therapy (3 Fractions)

RADIATION Involved-site Radiation Therapy (12 Fractions)

PROCEDURE Positron Emission Tomography

OTHER Questionnaire Administration

Locations Recruiting

Mayo Clinic in Arizona

United States, Arizona, Scottsdale


Mayo Clinic in Florida

United States, Florida, Jacksonville


Mayo Clinic in Rochester

United States, Minnesota, Rochester


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.